Docket #: S93-019
Cell Line Producing Soluble HLA-B7 - ATCC: J27-B7 (ATCC CRL-2374), C1R-B7 (ATCC® CRL-2371™)
The general purposes of this invention are 1) to provide bulk quantities of relatively pure soluble antigens of the human major histocompatibility complex; and 2) to determine whether or not soluble forms of the normally surface-bound HLA antigens could be used for diagnostic purposes and to test if they would induce tolerization rather than the immune sensitization caused by the surface bound form of those antigens. The first model used produced the HLA-B7 antigen in soluble form.
Deposited at ATCC: J27-B7 (ATCC CRL-2374)
C1R-B7 (ATCC® CRL-2371™)
Publications
- Hum Immunol. 1994 Jul;40(3):228-34.; "Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization."; Grumet FC1, Krishnaswamy S, See-Tho K, Filvaroff E, Hiraki DD.
- Hum Immunol. 1994 Jul;40(3):235-46.; "Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization."; Hiraki DD1, See-Tho K, Filvaroff E, Krishnaswamy S, de Bello W, Taidi-Laskowski B, Grumet FC.
Similar Technologies
-
Targeting a novel gene in human embryonic stem cells creates unique strategies for isolating and analyzing developing endoderm S10-347Targeting a novel gene in human embryonic stem cells creates unique strategies for isolating and analyzing developing endoderm
-
Multidrug (Pleiotropic) Resistant Cell Line, MES-SA/Dx5 S01-102Multidrug (Pleiotropic) Resistant Cell Line, MES-SA/Dx5
-
Analysis and optimization of gene expression using synthetic promoters S11-222Analysis and optimization of gene expression using synthetic promoters